Atacicept
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Background and aims Atacicept targets B-cell stimulating factors, BLyS and APRIL. ADDRESS II was a phase IIb, multicenter study…
Immunotherapy targeting B-cell populations has been found to slow disease progression in multiple sclerosis (MS). Recently…
Background SLE is associated with abnormal B cell activity, including elevated titers of IgG and anti-dsDNA antibodies (abs), and…
Background Atacicept is a fully human, recombinant fusion protein that inhibits B cell-stimulating factors APRIL and BLyS.1…
Atacicept, a specific inhibitor of BLys and APRIL, was used in a phase I study for 14 patients with myeloma (MM) and 4 with…
Despite atacicept showing promise in preclinical and phase I studies, new results from two randomized, placebo-controlled, phase…
Atacicept, a fully human recombinant fusion protein that blocks the activity of BLyS (B-Lymphocyte Stimulator) and APRIL (a…
Multiple sclerosis (MS) has traditionally been considered to be a T cell-mediated disease. However, there is an increasing body…
3029 Background: B-CLL cells are resistant to apoptosis and thus exhibit prolonged survival and accumulation in vivo. Exogenously…
Background: APRIL (A Proliferation-Inducing Ligand) and BLyS (B Lymphocyte Stimulator) are potent survival factors for normal B…